000 | 01960 a2200553 4500 | ||
---|---|---|---|
005 | 20250517002318.0 | ||
264 | 0 | _c20151124 | |
008 | 201511s 0 0 eng d | ||
022 | _a1521-009X | ||
024 | 7 |
_a10.1124/dmd.114.061218 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSharma, Raman | |
245 | 0 | 0 |
_aComparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment. _h[electronic resource] |
260 |
_bDrug metabolism and disposition: the biological fate of chemicals _cFeb 2015 |
||
300 |
_a190-8 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial, Phase I; Comparative Study; Journal Article | ||
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 | _aAnimals, Inbred Strains |
650 | 0 | 4 | _aBiotransformation |
650 | 0 | 4 | _aCarbon Radioisotopes |
650 | 0 | 4 | _aDogs |
650 | 0 | 4 | _aDrug Evaluation, Preclinical |
650 | 0 | 4 |
_aEnzyme Activators _xanalysis |
650 | 0 | 4 |
_aFeces _xchemistry |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aGlucokinase _xchemistry |
650 | 0 | 4 | _aHalf-Life |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHypoglycemic Agents _xanalysis |
650 | 0 | 4 |
_aImidazoles _xanalysis |
650 | 0 | 4 |
_aLiver _xdrug effects |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aMolecular Structure |
650 | 0 | 4 |
_aNicotinic Acids _xanalysis |
650 | 0 | 4 | _aOrgan Specificity |
650 | 0 | 4 | _aRats, Sprague-Dawley |
700 | 1 | _aLitchfield, John | |
700 | 1 | _aBergman, Arthur | |
700 | 1 | _aAtkinson, Karen | |
700 | 1 | _aKazierad, David | |
700 | 1 | _aGustavson, Stephanie M | |
700 | 1 | _aDi, Li | |
700 | 1 | _aPfefferkorn, Jeffrey A | |
700 | 1 | _aKalgutkar, Amit S | |
773 | 0 |
_tDrug metabolism and disposition: the biological fate of chemicals _gvol. 43 _gno. 2 _gp. 190-8 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1124/dmd.114.061218 _zAvailable from publisher's website |
999 |
_c24343022 _d24343022 |